Mark. A Glickman
2019
In 2019, Mark. A Glickman earned a total compensation of $624.4K as Chief Commercial Officer at Esperion Therapeutics, a 93% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $176,000 |
|---|---|
| Salary | $440,000 |
| Other | $8,392 |
| Total | $624,392 |
Glickman received $440K in salary, accounting for 70% of the total pay in 2019.
Glickman also received $176K in non-equity incentive plan and $8.4K in other compensation.
Rankings
In 2019, Mark. A Glickman's compensation ranked 11,085th out of 13,971 executives tracked by ExecPay. In other words, Glickman earned more than 20.7% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 11,085 out of 13,971 | 21st |
Division Manufacturing | 4,490 out of 5,701 | 21st |
Major group Chemicals And Allied Products | 1,761 out of 2,200 | 20th |
Industry group Drugs | 1,515 out of 1,886 | 20th |
Industry Pharmaceutical Preparations | 1,122 out of 1,398 | 20th |
Pay ratio
| Mark. A Glickman's Pay | $624,392 |
|---|---|
| Median Employee's Pay | $242,988 |
| Pay Ratio | 3to 1 |
In 2019, the annual total compensation of Mark. A Glickman was $624,392.
The annual total compensation of the median employee at Esperion Therapeutics was $242,988.
The ratio of Mark. A Glickman's pay to the pay of median employee was therefore 3 to one.
Source: SEC filing on April 16, 2020.
Glickman's colleagues
We found two more compensation records of executives who worked with Mark. A Glickman at Esperion Therapeutics in 2019.